Asthma and COPD Management with Symbicort

Introduction to Symbicort Dosing

The American College of Chest Physicians recommends that patients with severe COPD and a history of exacerbations use 2 inhalations of 160/4.5 mcg twice daily, which improves symptom scores and health status beyond bronchodilator monotherapy 2
The European Respiratory Society suggests that this dose is reserved for patients with FEV₁ <50% predicted and ≥2 exacerbations per year requiring antibiotics/oral steroids or ≥1 hospitalization 3

The National Asthma Education and Prevention Program recommends that patients with mild-to-moderate persistent asthma use a low-dose ICS/LABA combination, which reduces mild exacerbations by 40% and severe exacerbations by 29% 1
For patients with moderate-to-severe persistent asthma, the Global Initiative for Asthma recommends a dose of 2 inhalations of 160/4.5 mcg twice daily, corresponding to 400-800 mcg budesonide daily range 1

The Global Initiative for Chronic Obstructive Lung Disease recommends that patients with severe COPD and a history of exacerbations use 2 inhalations of 160/4.5 mcg twice daily, which improves lung function and reduces exacerbations 2, 3

The American Thoracic Society recommends maintaining the initial dose for at least 4 weeks before considering reduction, and titrating down to the minimum effective dose after achieving control 1
The European Respiratory Society suggests monitoring inhaler technique, symptom relief, and FEV₁ at regular intervals, and considering calcium/vitamin D supplementation for high-dose ICS (≥1,000 mcg/day) 1

The American Academy of Allergy, Asthma, and Immunology recommends that patients with asthma must be on adequate ICS before adding LABA, and that COPD patients should not use Symbicort in asthma or as monotherapy 1, 2, 3
The American College of Chest Physicians suggests considering adding tiotropium or oral corticosteroids at Step 5-6 before increasing Symbicort beyond maximum doses, and referring patients who require >800 mcg budesonide daily for phenotypic assessment for biologics 5

The Journal of Allergy and Clinical Immunology recommends using Symbicort for SMART therapy in patients with moderate-to-severe asthma, which reduces severe exacerbations by 39% compared to higher-dose ICS alone 4
The American Thoracic Society suggests that this approach results in 31 more asthma control days per patient-year, but notes that it is currently off-label use in the United States 4